



Scientific  
**Sessions**



American  
Heart  
Association.

#AHA22

[ScientificSessions.org](https://ScientificSessions.org)

# Symposia Schedule & Locator Guide

YOUR GUIDE TO UNOFFICIAL PROGRAMMING

These events are not part of the official Scientific Sessions 2022  
as planned by the AHA Committee on Scientific Sessions Program.



This publication is supported by paid advertisement.

Paid Advertisement

Register online at:

**WWW.SYMPOSIAREG.COM/22210**

# Managing Patients with Recent Worsening Heart Failure with Reduced Ejection Fraction: Keys to Successful Outcomes

**Saturday, November 5, 2022**

Dinner and Registration: 6:00 pm - 6:30 pm CT

Symposium: 6:30 pm - 8:00 pm CT

**Marriott Marquis Chicago**

Ballroom: Great Lakes FG

2121 South Prairie Avenue

Chicago, Illinois



Chair

**John Teerlink, MD**

Faculty

**Nancy Albert, PhD, RN**

**Barry Greenberg, MD**

**Scott Solomon, MD**

**Jane Wilcox, MD, MSc**



Scan this code  
to register

This program is  
sponsored by



This activity is supported by an  
independent educational grant  
from Cytokinetics Incorporated.



**This event is not part of the official Scientific Sessions 2022  
as planned by the AHA Committee on Scientific Sessions Programming.**



**See pages 8-9 for map and addresses of symposia locations.**

### SYMPOSIA SCHEDULE IS CENTRAL TIME

#### Friday, Nov. 4

##### **Case Challenges With Antiplatelet Therapy**

**Dinner and Registration: 6-6:30 p.m.**

**Symposia: 6:30-8 p.m.**

*Marriott Marquis Chicago, Great Lakes FG Ballroom*

Dual antiplatelet therapy (DAPT) remains the cornerstone of therapy for the prevention of ischemic complications after PCI. However, the reduction in risk of ischemic events with DAPT comes at a cost of increased bleeding; patients at high bleeding risk (HBR) may be effectively and safely managed with antiplatelet therapy bleeding risk-reduction strategies. Conversely, other patients at high ischemic risk after full-term DAPT may be candidates for either extended DAPT or dual pathway inhibition (DPI), consisting of aspirin (ASA) plus factor Xa inhibition. In this program, experts in the use of antiplatelet therapy (Program Chair Dr. Deepak Bhatt, with faculty members Dr. Marc Bonaca, Dr. Roxana Mehran and Dr. Philippe Gabriel Steg) will describe best practices for assessing ischemic risk and bleeding risk after PCI, and in three challenging cases, supported by current clinical trial evidence, identify patients for bleeding risk-reduction strategies with antiplatelet therapy, and patients for consideration of prolonged dual therapy.

**SPONSOR:** VoxMedia

**SUPPORTER:** AstraZeneca

**Register online at [www.symposiareg.com/22211](http://www.symposiareg.com/22211)**

#### Saturday, Nov. 5

##### **Making the Call in Heart Failure: Multidimensional Outcomes With SGLT2 Inhibitors**

**6-7:30 a.m.**

*Marriott Marquis Chicago, Grand Horizon Ballroom – Section EF*

Heart failure medicine is dynamic, with recent approvals for use of SGLT2 inhibitors, and updated recommendations for definition, staging and classification of heart failure. As heart failure therapies overlap into other specialties, it is more important than ever to use a patient-centered, multidisciplinary care team model. In this 90-minute Call-a-Colleague presentation, three experts will discuss the new consensus recommendations for heart failure and the evidence for using SGLT2 inhibitors in patients with different classes of heart failure as well as comorbidities. To illustrate how to individualize treatment regimens and the nuances of heart failure care, they will call in specialist colleagues for consults about practical considerations for prescribing SGLT2 inhibitors.

**SPONSOR:** Global Education Group and Integrity Communications

**SUPPORTER:** AstraZeneca

**Registration: <https://www.exchangecme.com/HFChicago22>**

### Saturday, Nov. 5 (continued)

---

#### **Breaking Through the Resistance: Innovations Surrounding Resistant Hypertension**

**6-7:30 a.m.**

*Marriott Marquis Chicago, Great Lakes Ballroom AB, Level 2*

When patients present with resistant hypertension, clinicians aim to stabilize blood pressure by adding or replacing traditional agents, then hope that noncompliance and reduced adherence won't further complicate management. Fortunately, new and effective pharmacologic treatments, device therapies and multidisciplinary team approaches are rapidly changing outcomes. This CE-certified symposium will assess diagnostic delay consequences, traditional treatment shortfalls, dual endothelin-receptor antagonists and why guidelines don't keep pace with real-world clinical practice.

**SPONSOR:** Janssen

**SUPPORTER:** TotalCME

**Register online at [www.mededotg.com/rHTN](http://www.mededotg.com/rHTN)**

---

#### **Updating Our Cardio-Oncology Skills in the Cancer Immunotherapy Era: Team-Based Strategies for Risk Assessment, Diagnosis and Management of Myocarditis and Other Cardiac Immune-Related Adverse Events**

**6-7:30 a.m.**

*Hyatt Regency McCormick Place, Prairie Room*

Immune checkpoint inhibitors (ICIs) have had a strikingly positive impact on the treatment of a range of cancer types by blocking intrinsic downregulators of the immune response to increase antitumor immunity. A number of ICIs and ICI-based combinations have been approved for use in many solid and liquid malignancies, and intense research efforts promise to expand their role in advanced cancers and early-stage, curative-intent settings. While immunotherapy has become a pillar of cancer treatment and is considered safe, ICIs are associated with a spectrum of unique toxicities termed immune-related adverse events (irAEs). These irAEs can affect any organ system in the body, including the heart and cardiovascular system, occur at any point during or after treatment, and vary in presentation from mild to severe, and sometimes life threatening. Cardiac pathology attributed to irAEs include myocarditis, cardiomyopathy, pericardial disease, arrhythmias and conduction disease, impaired ventricular function with heart failure and vasculitis. Autoimmune myocarditis is the most common and best characterized cardiac irAE to date. This PeerView Live Clinical Consults cardio-oncology symposium will provide essential guidance for prompt identification and initiation of treatment of irAEs. In the current era of cancer immunotherapy, health care professionals must develop a high level of vigilance and be able to correctly and rapidly manage and monitor patients with cancer-exhibiting symptoms of possible cardiac irAEs to ensure the best possible outcomes. The expert faculty will present management algorithms, real-world case scenarios and practical challenges related to multidisciplinary coordination of care to improve collaborative mitigation of cardiac irAEs.

**SPONSOR:** PVI, PeerView Institute for Medical Education

**SUPPORTER:** Bristol Myers Squibb

**Register online at: [PeerView.com/CardioOnc22-Live](http://PeerView.com/CardioOnc22-Live)**

## Saturday, Nov. 5 (continued)

**How I Think, How I Treat: Cardiology-Focused Perspectives on Using SGLT2 Inhibitors to Optimize Outcomes in Patients With Heart Failure****6-7:30 p.m.****Marriott Marquis Chicago, Grand Horizon Ballroom E**

SGLT2 inhibitors have a newly established role in the foundation of guideline-directed medical therapy for patients with heart failure (HF). As the understanding of these agents has evolved beyond their use in diabetes care, SGLT2 inhibitors have earned a place as vital pharmacotherapy in the fight against heart failure. Landmark clinical trials of SGLT2 inhibitors have shown clinically relevant and statistically significant reductions in hospitalization for HF events, major adverse cardiovascular events and kidney events.

In PeerView's latest CME-certified in-person and virtual event, experts reveal their personal approach to how they think about and treat patients with HF using SGLT2 inhibitors. Follow along from the beginning of the treatment journey with the identification of patients who are most likely to benefit. Then, learn how to take action and apply the evidence for using SGLT2 inhibitors in patients with HFrEF, HFpEF or acute HF. Finally, shift your focus to patient-centered care by reviewing strategies and guidance for integrating SGLT2 inhibitors into your practice.

**SPONSOR:** PVI, PeerView Institute for Medical Education**SUPPORTER:** Boehringer Ingelheim, Eli Lilly and Company**Register online at [PeerView.com/2022HF-Live](https://www.peerview.com/2022HF-Live)**

PAID ADVERTISEMENT

# MAKING THE CALL IN HEART FAILURE

## Multidimensional Outcomes with SGLT2 Inhibitors

### SATURDAY, NOVEMBER 5

#### 6:00 AM – 7:30 AM

5:30 AM - 6:00 AM - Registration & Breakfast

**GRAND HORIZON BALLROOM – SECTION EF**  
Marriott Marquis Chicago



### REGISTER TODAY

[ExchangeCME.com/  
HFChicago22](https://www.ExchangeCME.com/HFChicago22)

This event is not part of the official Scientific Sessions Conference 2022 as planned by the AHA Committee on Scientific Sessions Programming.

This activity is jointly provided by Global Education Group and Integritas Communications.  
This activity is supported by an educational grant from AstraZeneca.

### Saturday, Nov. 5 (continued)

---

#### **IV Iron Expert Exchange: Data-Driven Debates on the Revolutionary Role of IV Iron in Heart Failure**

**6-7:30 p.m.**

*Marriott Marquis Chicago, Grand Horizon Ballroom G, Level 4*

**SPONSOR/SUPPORTER:** CEC

**For more information and to register, visit:**

**[www.ceconcepts.com/content/iv-iron-expert-exchange](http://www.ceconcepts.com/content/iv-iron-expert-exchange)**

---

#### **Managing Patients With Recent Worsening Heart Failure With Reduced Ejection Fraction: Keys to Successful Outcomes**

**6:30-8 p.m.**

*Marriott Marquis Chicago, Great Lakes FG Ballroom*

Patients with heart failure with reduced ejection fraction (HFrEF) and recent worsening heart failure (WHF) have high rates of death and hospitalization despite the use of guideline-directed medical therapy (GDMT). New and emerging novel agents, with distinct mechanisms of action, have demonstrated improved clinical outcomes in these patients, and clinicians must be able to not only identify appropriate patients for these therapies—personalizing treatment based on the patient's profile—but also utilize these therapies effectively in practice. Therefore, in this program, HF experts (Chair Dr. John Teerlink, with faculty members Dr. Nancy Albert, Dr. Barry Greenberg, Dr. Scott Solomon and Dr. Jane Wilcox) will explain the challenges in managing patients with HFrEF and recent WHF, identify the roles for new and emerging therapies and describe best practices to prevent adverse HF-related events.

**SPONSOR:** VoxMedia

**SUPPORTER:** Cytokinetics, Inc

**Register online at [www.symposiareg.com/22210](http://www.symposiareg.com/22210)**

---

#### **From Cell to Bedside—Transforming the Care of the Cardiac Patient**

**7:30-9 p.m.**

*Sable at Navy Pier Chicago, Grand Horizon Ballroom EF*

Educational talks on the state-of-the-art and novel approaches to the care of patients with heart disease.

**SPONSOR/SUPPORTER:** Rush University Medical Center

**<https://www.eventbrite.com/e/from-cell-to-bedside-transforming-the-care-of-the-cardiac-patient-tickets-439003038907>**

---

#### **ABC's Dr. Walter M. Booker, Sr. Memorial Symposium**

**"Structural Racism and Healthcare Disparity: Cause or Effect?"**

**7:30-9 p.m.**

*Marriott Marquis Chicago/Grand Horizon Ballroom, Section A, 4th Floor*


This program will discuss structural racism and its impact on health disparities, specifically focusing on the African American Community. The speakers will present the need to make cardiovascular equity a priority for Black patients with cardiovascular disease and the next steps to progression. Expert panelists will discuss action items to address these issues and achieve health equity.

**SPONSOR/SUPPORTER:** Association of Black Cardiologists, Inc.

**Register online at [www.cognitoforms.com/](http://www.cognitoforms.com/)**

**[AssociationOfBlackCardiologistsInc1/ABCEventsAtAHA22](https://www.cognitoforms.com/AssociationOfBlackCardiologistsInc1/ABCEventsAtAHA22)**

---



# IV Iron Expert Exchange: Data-driven Debates on the Revolutionary Role of IV Iron in Heart Failure

**Saturday, November 5, 2022** | Marriott Marquis Chicago, Grand Horizon Ballroom G (Level 4)

5:30 PM-6:00 PM Registration | 6:00 PM-7:30 PM Presentation

## LEARNING OBJECTIVES

- Discuss the fundamental principles of iron metabolism and absorption, with a focus on how these principles apply to treatment of iron deficiency (ID) in heart failure (HF), and identify key distinctions between HFrEF and HFpEF.
- Recognize the robust impact of comorbid ID and HF, with or without concomitant anemia, and describe the prognostic implications of ID on patient functional capacity, quality of life, and HF morbidity and mortality outcomes.
- Evaluate the essential utility of serum ferritin and transferrin saturation (TSAT) as ID diagnostic laboratory indices in HF, and as foundational clinical parameters for guiding treatment with intravenous (IV) iron.
- Appraise completed, ongoing, and planned clinical trials of IV iron therapies for ID in HF, and identify pivotal data readouts that have influenced current practice and consensus HF guideline statements (2021 ESC and 2022 ACC/AHA/HFSA).
- Understand how the innovative nanoparticle design of next-generation IV iron products improves upon the safety profiles of earlier generation products, with anaphylaxis rates as low as 0.1%.
- Using a case-based format, analyze how pro-inflammatory cytokines and elevated hepcidin levels impact the comparative clinical utility of oral vs IV iron supplementation modalities in HFrEF.

## AGENDA

**5:30 PM-6:00 PM**  
Registration

**6:00 PM-6:10 PM**  
Welcome/Intro/Pre-test

**6:10 PM-6:35 PM**  
Setting the Stage:  
Pathophysiology and  
Patient Impact of ID in HF

**6:35 PM-7:20 PM**  
Case-Based Expert  
Exchange: The Evolving  
Role of IV Iron in the  
HFrEF Paradigm

**7:20 PM-7:30 PM**  
Conversations with  
the Experts/Audience  
Q&A/Post-test

## FACULTY



**Muthiah Vaduganathan, MD,  
MPH (Activity Chair)**  
Harvard Medical School  
Boston, MA



**Biykem Bozkurt, MD, PhD,  
FHFS, FACC, FAHA, FACP**  
Baylor College of Medicine  
Houston TX



**Robert J. Mentz, MD**  
Duke University Medical Center  
Durham, NC

## ACCREDITATION


This live educational activity is designated for a maximum of 1.5 ACCME/ANCC/ACPE credits.

Presented by Creative Educational Concepts, LLC. Supported through an independent educational grant from American Regent.

*This event is not part of the official Scientific Sessions Conference 2022 as planned by the AHA Committee on Scientific Sessions Programming.*

Scan for information  
and to register.



 **SCAN ME**




# Symposia Locations



- 1 Hyatt Regency Chicago**  
151 E. Wacker Drive
- 2 Hyatt Regency McCormick Place\***  
2233 S. Martin Luther King Drive
- 3 Marriott Marquis Chicago\***  
2121 S. Prairie Ave.
- 4 Sable at Navy Pier Chicago**  
900 E. Grand

\*Headquarter hotels for Scientific Sessions 2022

Paid Advertisement


 **INTERACTIVE CME IN-PERSON AND VIRTUAL SYMPOSIUM, EARN CREDIT!**


**Integrating Novel Cardiac Myosin Inhibitors into the Management of Hypertrophic Cardiomyopathy:**  
**Practical Strategies for Diagnosis and Treatment**


 


Presented by leading experts in the field of HCM,  
**Milind Desai, MD, MBA, and Anjali Tiku Owens, MD**

**SATURDAY**  
**NOVEMBER 5**

 **Marriott Marquis Chicago**  
Grand Horizon Ballroom AB, Level 4

 **7:30 PM – 8:00 PM** Registration & Dinner  
**8:00 PM – 9:00 PM** Symposium



**Scan the QR code to register.** 

**This event is not part of the official Scientific Sessions Conference 2022 as planned by the AHA Committee on Scientific Sessions Programming.**  
This CME activity is jointly provided by Global Education Group and Answers in CME.  
There is no fee to participate in this activity.  
This activity is supported through an educational grant from Bristol Myers Squibb.  
Please contact [live@answersincme.com](mailto:live@answersincme.com) for more information.  
© 2018-2022, Answers in CME.

## 2022 SYMPOSIA SCHEDULE AND LOCATOR GUIDE

### Saturday, Nov. 5 (continued)

---

#### Integrating Novel Cardiac Myosin Inhibitors Into the Management of Hypertrophic Cardiomyopathy: Practical Strategies for Diagnosis and Treatment

7:30 – 9 p.m.

*Marriott Marquis Chicago, Great Lakes Ballroom A-B, Level 4*

In this live in-person and virtual symposium, cardiovascular disease experts discuss the best practices to facilitate early diagnosis of HCM and evidence-based strategies to integrate novel cardiac myosin inhibitors into treatment plans for patients with obstructive HCM.

**SPONSOR:** Answers in CME

**SUPPORTER:** Bristol Myers Squibb

Scan the QR code to register:



### Sunday, Nov. 6

#### Obesity as a Cardiovascular Risk Factor: Assessment and Management

6-7:30 a.m.

*Hyatt Regency McCormick Place, Jackson Park*

Obesity is an epidemic that has serious adverse effects on patients seen by cardiologists. This educational program will inform cardiologists about the effects of obesity on CVD, HF, and dysrhythmias and the benefit of weight loss, the efficacy and safety of agents FDA-approved to manage obesity and provide guidelines for starting and intensifying obesity treatment through shared decision making with patients.

**SPONSOR:** Novo-Nordisk

**SUPPORTER:** Rockpointe

Register online at: [www.rockpointe.com/Obesity-CVRiskFactor](http://www.rockpointe.com/Obesity-CVRiskFactor)

---

#### Real-World Perspectives on the Under-Diagnosis of Heart Failure in the U.S.

6-7:30 a.m.

*Marriott Marquis Chicago, Grand Horizon Ballroom EFG*

This session will discuss the underdiagnosis of heart failure (HF) and its impact on patients in the real-world setting. The session will open with a compelling story from a patient turned advocate who has lived through challenges in diagnosis and treatment for heart failure and related complications for 20 years. The program will continue with a real-world data presentation on the under-utilization of diagnostic tools to identify HF in the U.S. This will be followed by an insightful panel discussion among several heart failure specialists and a patient advocate to illuminate gaps, challenges and opportunities in the diagnosis of heart failure.

**SPONSOR/SUPPORTER:** Roche Diagnostics

Register online at: [https://docs.google.com/forms/d/1\\_YdDe7tUbn1jagJYejLgqJiU4JCOB9eoEyOrXivG5qQ/viewform?edit\\_requested=true](https://docs.google.com/forms/d/1_YdDe7tUbn1jagJYejLgqJiU4JCOB9eoEyOrXivG5qQ/viewform?edit_requested=true)

**EARN UP TO 1.5 CME/CE CREDITS**



## CME DINNER SYMPOSIUM

**Join George Bakris alongside Pam Taub, Sylvia Rosas, and Rajiv Agarwal to discuss the latest in cardiorenal outcomes with novel nonsteroidal MRAs!**

**Sunday, November 6, 2022 | 7:30 p.m. – 9:00 p.m.  
Marriott Marquis Chicago | Room: Great Lakes EF**

### AGENDA

#### Opening Remarks and Introductions

#### Cardiovascular Protection in Patients with Chronic Kidney Disease (CKD) and Type 2 Diabetes (T2D)

- CKD as a cardiovascular risk factor
- The importance of identifying CKD to improve CVD risk assessment: new implications and perspectives

#### Novel Nonsteroidal MRAs in Patients with CKD and T2DM

- Rationale and mechanisms of action
- Cardiorenal risk reduction: evidence from clinical trials

#### The Role of Nonsteroidal MRAs in Cardiovascular Care

- How nonsteroidal MRAs fit in with other cardioprotective therapies
- Guideline updates & patient selection

#### Patient Case, Panel Discussions and Future Directions

#### Q & A and Conclusions

**Pre-Register and Reserve Your Seat at  
[www.cardiometabolichealth.org/AHA2022](http://www.cardiometabolichealth.org/AHA2022) Today!**

**Don't forget to also visit CMHC's Booth at A-608!**



This activity is jointly provided by Global Education Group and Cardiometabolic Health Congress.

This satellite symposium is supported by an educational grant from Bayer HealthCare Pharmaceuticals Inc.

**This event is not part of the official Scientific Sessions Conference 2022 as planned by the AHA Committee on Scientific Sessions Programming.**

### Sunday, Nov. 6 (continued)

---

#### **Advances in Imaging and Targeted Management for Cardiac Inflammation: Clinical Progress in Pericarditis** **6-7:30 p.m.**

*Hyatt Regency McCormick Place, Prairie Room*

Pericarditis is a painful and debilitating autoinflammatory cardiovascular disease (CVD). It is the most common disease of the pericardium, comprising nearly 5% of emergency department visits with patients who present with nonischemic chest pain. Though generally self-limiting, pericarditis can come with a significant risk of acute complications and recurrences. The recurrence rate after an initial episode of pericarditis ranges from 15% to 30%, and may increase to 50% after a first recurrence in patients who are not treated appropriately.

Join our panel of experts for an interactive CME-certified symposium focused on enhancing clinician understanding of the clinical and humanistic burden of recurrent pericarditis, assessment strategies to facilitate early recognition and advances in targeted treatment strategies, with the goal of treating symptoms early and appropriately, reducing recurrence and optimizing patient outcomes in patients with pericarditis.

**SPONSOR:** Kiniksa

**SUPPORTER:** Medscape

**For more information and to register, visit:**

<https://na.eventscloud.com/website/44456/>

---

#### **Transforming the Treatment of Hypertrophic Cardiomyopathy: Key Updates on Sarcomere-Directed Therapies** **6-7:30 p.m.**

*Marriott Marquis Chicago, Great Lakes Ballroom*

Hypertrophic cardiomyopathy (HCM), the most common inherited cardiac disorder, is defined by the presence of increased left ventricular (LV) wall thickness that is not caused by secondary factors. Despite this high prevalence, the majority of individuals with HCM are undiagnosed and untreated. HCM is a disease of the sarcomeres, which are responsible for contraction within cardiac myocytes. Physicians must be able to understand the role of sarcomere dysfunction in the development of HCM and how cardiac myosin inhibitors disrupt these pathological processes. Additionally, they must be made aware of emerging clinical data surrounding cardiac myosin inhibitors to provide optimal care to their patients. This Town Hall does just that. We hope you join us and look forward to sharing this exciting information.

**SPONSOR/SUPPORTER:** Cytokinetics, Inc.

**For more information and to register, visit:**

[www.medscape.org/symposium/hcm-2022](http://www.medscape.org/symposium/hcm-2022)


---

#### **Ultrasound Renal Denervation (uRDN)—Leading With Evidence and Preparing for What Comes Next** **6-7:30 p.m.**

*Hyatt Regency McCormick Place, Jackson Park ABC*

Join ReCor Medical's dinner symposium to learn about ultrasound renal denervation therapy for treatment of uncontrolled hypertension.

**SPONSOR/SUPPORTER:** ReCor Medical

Roche

## Real World Perspectives on the Under-Diagnosis of Heart Failure in the US

**Sunday, November 6th**

**6:00 -7:30 am**

**Marriott Marquis, Chicago**

**Grand Horizon Ballroom EFG**

***Breakfast Provided***

Join leading cardiologists and other thought leaders as they discuss the under-diagnosis of heart failure and its impact on patients in the real world setting.

- **Hear the compelling story from a patient turned advocate** who has lived through challenges in diagnosis and treatment for heart failure.
- **See compelling real world data** on the under-utilization of diagnostic tools to identify heart failure, and the resulting implications.
- **Engage in an insightful panel discussion** to illuminate gaps, challenges and opportunities in the diagnosis of heart failure.

### **SPEAKERS:**

Rhonda E. Monroe, MBA

Muthiah Vaduganathan, MD MPH FACC

Stephen J. Greene, MD, FACC, FHFSa

Ambarish Pandey, MD, MSCS, FAHA

Ani John, PhD, MPH



**SCAN HERE  
TO REGISTER**

*Brought to you by Roche Diagnostics*

This event is not part of the official Scientific Sessions 2022 as planned by the AHA Committee on Scientific Sessions Program.

## 2022 SYMPOSIA SCHEDULE AND LOCATOR GUIDE

### Sunday, Nov. 6 (continued)

#### Expert Perspectives and Discussions: What You Need to Know About Optimizing Cardiorenal Outcomes With Novel Nonsteroidal MRAs

7:30-9 p.m.

*Marriott Marquis Chicago, Great Lakes EF Ballroom*

Join George Bakris alongside Pam Taub, Sylvia Rosas and Rajiv Agarwal to discuss the latest in cardiorenal outcomes with novel nonsteroidal MRAs.

Key reasons to attend this CME Dinner Symposium:

- Earn up to 1.5 CME/CE credits
- Learn more about the importance of chronic kidney disease and type 2 diabetes as major drivers of cardiovascular morbidity and mortality
- Be up-to-date about the data with novel nonsteroidal MRAs in cardiorenal risk reduction, and how this new approach fits in with existing treatment options
- Hear from top experts on how to apply this evidence to reduce the risk of cardiovascular and renal adverse events in patients with chronic kidney disease and type 2 diabetes

**SPONSOR/SUPPORTER:** Cardiometabolic Health Congress

Reserve your seat at: <https://www.cardiometabolichealth.org/aha2022>

#### JAMA Network Reception (Invitation-only event)

7:30-9 p.m.

*Hyatt Regency Chicago, Crystal C*

A reception with the editors of JAMA, JAMA Cardiology, JAMA Internal Medicine and JAMA Network Open.

**SPONSOR/SUPPORTER:** JAMA Network

### Monday, Nov. 7

#### Personalizing the Management of Hyperlipidemia: Addressing Unmet Needs Among High-Risk Patients With Atherosclerotic Cardiovascular Disease With Novel Lipid- Lowering Therapies

6-7:30 a.m.

*Hyatt Regency McCormick Place, Regency Ballroom CDE, Level 2*

LDL-C reduction with statin therapy is the cornerstone treatment for dyslipidemia, yet many patients are unable to attain recommended lipid goals with these oral therapies alone. PCSK9-targeting therapies, monoclonal antibodies and small-interfering RNA have been shown to reduce LDL-C levels by half, but questions surround the use of these agents and the outcomes associated with their use. In this PeerView Live MasterClass and Practicum, leading experts will discuss the latest data for these newer targeted strategies and offer evidence-based strategies to better individualize care to improve clinical outcomes, especially in patients with high ASCVD risk.

**SPONSOR:** PVI, PeerView Institute for Medical Education

**SUPPORTER:** Novartis

Register online at: [https://lrn.peerview.com/150207909\\_1/150207909\\_1\\_p1/stage1reg?Promocode=980&AudienceID=AHA&ProjectNumber=150207909\\_1&CountryID=US](https://lrn.peerview.com/150207909_1/150207909_1_p1/stage1reg?Promocode=980&AudienceID=AHA&ProjectNumber=150207909_1&CountryID=US)

[com/150207909\\_1/150207909\\_1\\_p1/stage1reg?Promocode=980&AudienceID=AHA&ProjectNumber=150207909\\_1&CountryID=US](https://lrn.peerview.com/150207909_1/150207909_1_p1/stage1reg?Promocode=980&AudienceID=AHA&ProjectNumber=150207909_1&CountryID=US)

PAID ADVERTISEMENT

REGISTER ONLINE AT:

**WWW.SYMPOSIAREG.COM/22211**



# Case Challenges with Antiplatelet Therapy

6:30 PM Introduction

**Deepak L. Bhatt, MD, MPH  
(Chair)**

6:35 PM Personalizing Antiplatelet Therapy After PCI:  
Assessment of Ischemic Risk and Bleeding Risk

**Deepak L. Bhatt, MD, MPH**

6:50 PM Case #1: Antiplatelet Therapy for the Patient with Coronary Artery Disease and Type 2 Diabetes Undergoing PCI

**Case Presenter:**

**Philippe Gabriel Steg, MD**

7:05 PM Case #2: Antiplatelet Therapy Strategies for the High Bleeding Risk Patient

**Case Presenter:**

**Roxana Mehran, MD**

7:20 PM Case #3: The Dilemma of Extending Dual Antiplatelet Therapy or Using Dual Pathway Inhibition

**Case Presenter:**

**Marc P. Bonaca, MD, MPH**

7:35 PM Take-Home Messages: Optimizing the Use of Antiplatelet Therapy—Finding the “Sweet Spot”

**Deepak L. Bhatt, MD, MPH**

7:45 PM Question and Answer

This event is not part of the official Scientific Sessions 2022 as planned by the AHA Committee on Scientific Sessions Programming.

This activity is supported by an educational grant from AstraZeneca Pharmaceuticals.

This program is sponsored by



Scan Here For More Information



**Friday, November 4, 2022**

Dinner and Registration:

6:00 PM – 6:30 PM CT

Symposium:

6:30 PM – 8:00 PM CT

**Marriott Marquis Chicago**

**Ballroom: Great Lakes FG**

2121 South Prairie Avenue  
Chicago, Illinois

**CHAIR**

**Deepak Bhatt, MD, MPH**

**FACULTY**

**Marc Bonaca, MD, MPH**

**Roxana Mehran, MD**

**PG Steg, MD**



# Transforming the Treatment of Hypertrophic Cardiomyopathy

## Key Updates on Sarcomere-Directed Therapies

**NOVEMBER 6, 2022 | 6:00 PM – 7:30 PM CT**

**REGISTRATION AND MEAL: 5:30 PM – 6:00 PM CT**

**PRESENTATION: 6:00 PM – 7:30 PM CT**



MARRIOTT MARQUIS  
2121 SOUTH PRAIRIE AVENUE | CHICAGO, ILLINOIS  
GREAT LAKES BALLROOM A-B

### MODERATOR



#### **Martin S. Maron, MD**

Director of the Hypertrophic Cardiomyopathy Center  
Lahey Hospital & Medical Center  
Burlington, Massachusetts

### PANELISTS



#### **Ahmad Masri, MD, MS**

Assistant Professor of Medicine  
Oregon Health & Science University  
Director, Hypertrophic Cardiomyopathy Center  
Director, Cardiac Amyloidosis Program  
Portland, Oregon



#### **Carolyn Ho, MD**

Associate Professor  
Harvard Medical School  
Cardiovascular Medicine  
Brigham and Women's Hospital  
Medical Director of the Cardiovascular Genetics Center  
Boston, Massachusetts



#### **Christopher M. Kramer, MD**

Distinguished Professor of Cardiovascular Medicine  
George A. Beller MD/Lantheus Medical Imaging  
Charlottesville, Virginia

For more information and to register, visit:

**[www.medscape.org/symposium/hcm-2022](http://www.medscape.org/symposium/hcm-2022)**

This event is not part of the official Scientific Sessions 2022 as planned by the AHA Committee on Scientific Sessions Program.